HealthEd Seminar: The Annual Women’s & Children’s Health Update 2022 Banner

Category: Medical Professional News

HealthEd Seminar: The Annual Women’s & Children’s Health Update 2022

Leading experts present their independent views and advice in 2022  Brisbane – 4 June | Sydney – 6 August | Perth – 27 August… Continue Reading →

Read more

Adelaide Event: Menopause Essentials Update – 4th June

Menopause Essentials Update ABOUT This update on Menopause is aimed at GP’s, gynaecologists, endocrinologists and other health professionals who are seeking a comprehensive review… Continue Reading →

Read more

What is HSDD? – Patient Resource

Patient Resource – Website What is HSDD? Hypoactive sexual desire dysfunction (HSDD) is an extremely common medical condition that causes distress resulting from a… Continue Reading →

Read more

IMS: Sexual wellbeing after menopause

Patient Support Material: Free yourself and embrace positive sexual wellbeing Sexual health is a state of physical, emotional, mental and social wellbeing related to… Continue Reading →

Read more

Share your opinions as a woman with POI/ Premature menopause.

International POI guideline update survey What matters for you? A 10 minute scoping survey for women or for health professionals: An international collaboration between the European… Continue Reading →

Read more

Jean Hailes: National Women’s Health Survey

National Women’s Health Survey Welcome to Jean Hailes survey This survey was developed by Jean Hailes for Women’s Health and a team of experts…. Continue Reading →

Read more

Monash University: Bone Density Study

A study to prevent bone loss and restore sexual function in women with primary ovarian insufficiency Melbourne and Perth As many as 4 in… Continue Reading →

Read more

AndroFeme 1 licensed for hypoactive sexual desire dysfunction in postmenopausal women

Lawley Pharmaceuticals  has obtained approval for registration of AndroFeme® 1 in the Australian Register of Therapeutic Goods (ARTG) for the treatment of postmenopausal women… Continue Reading →

Read more

Tanner Pharma Group and Lawley Pharmaceuticals Initiate Global Named Patient Program for AndroFeme® 1

Friday 12th June 2020 Perth, Australia and Charlotte, USA – Lawley Pharmaceuticals and Tanner Pharma Group announced today that they have initiated a global… Continue Reading →

Read more

TGA accepts AndroFeme 1 for evaluation in postmenopausal women with Hypoactive Sexual Desire Dysfunction.

TGA accepts AndroFeme 1 for evaluation in postmenopausal women with HSDD. Perth, Western Australia; Dec. 05, 2019  — Lawley Pharmaceuticals today announced AndroFeme 1,… Continue Reading →

Read more